https://www.selleckchem.com/products/tmp269.html
Superior OS benefit from ICI combination therapy than that in monotherapy was observed in patients with BMs (HR, 0.49 0.81, P = 0.005) but not in patients without BMs (HR, 0.71 0.76, P = 0.27). There was no compelling statistical evidence that the efficacy of ICIs in metastatic NSCLC was modified by the presence of asymptomatic and/or treated BMs. Patients with BMs were likely to obtain more OS benefit from ICI combination therapy than that from monotherapy. There was no compelling statistical evidence that the efficacy of ICIs in metast
Like
Comment
Share
